Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10585019
Filing Date		2006-06-29
First Named Inventor	Helle	Wittorff
Art Unit		1761
Examiner Name		
Attorney Docket Number		GRP-0168

U.S.PATENTS						Remove
Examiner Cite Initial* Code1		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	2007965		1935-07-16	Cartton Ellis	
	2	2353927		1942-10-05	Oscar A. Pickett	
3 26		2635964		1951-01-23	Eric J. Hewitt	
	4	3262784		1966-07-26	Robert C. Bucher	
	5	4525363		1985-06-25	Ronald P. D'Ameilia	
	6	4731435		1988-03-15	Robin N. Greene, et al.	
	7	5354556		1994-10-11	Randall T. Sparks	
If you wish	to a	dd additional U.S. Pa	tent citatio	n information p	lease click the Add button.	Add Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10585019
Filing Date		2006-06-29
First Named Inventor Helle		Wittorff
Art Unit		1761
Examiner Name		
Attorney Docket Number		GRP-0168

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where	
	1	20060147580	A1	2006-07	7-06	Vibeke Nissen					
If you wis	f you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	hd de4 Publication Date Name of Patentee or Applicant of cited Document Pages, Column where Relevan Passages or R Figures Appea		levant or Relevant	TS		
	1	1354908	EP			2003-10-22					
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NO	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dity and/or country where published.				Τs						
	CHING, CHAUNCEY, et al., "Biodegradable Polymers and Packaging", Biodegradable Polymers and Packaging, (1999): pg. 28-31										
	2 GRUPMA, DIRK W., et al., "(Colpolymens of L-lactide, 1" Macromolecules Chem. Phys. (1993): pg. 1633-1647										
	3 JP06-046760; 22-02-1994, Patient Abstracts of Japan (2 pages)										
	4 JP48-19950, 18-06-1973; Translation (10 pages)										
If you wish	f you wish to add additional non-patent literature document citation information please click the Add button Add										

| Application Number | 10050519 | Filing Date | 2006-06-29 | Filing Date |

	EXAMINER SIGNATURE							
Examiner Signature		Date Considered						
	reference considered, whether or not citation is in conformar rmance and not considered. Include copy of this form with							

See Kinc Ooke of USPTO Patent Documents at www.ISPTO.GOV or MPEP 901.04. I Enter office that issued the document, by the Involvation (WIPO Standard S13.) "Extra office This papers operated counters, the involvation of the year of the integer or impreced the serial running represent the serial running of the Empirer name precede the serial running of the Empirer name precede the serial running of the Empirer name precedes the serial running of the Empirer name of the Empirer

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10585019		
Filing Date		2006-06-29		
First Named Inventor	Helle	Wittorff		
Art Unit		1761		
Examiner Name				
Attorney Docket Number		GRP-0168		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

٦	See	attached	certification	statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

NA NAS

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Roberta L. Pelletier/	Date (YYYY-MM-DD)	2006-11-10
Name/Print	Roberta I Pelleber	Registration Number	46372

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.